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Sirs: In the last few years many
studies have demonstrated that
statins, in addition to their lipid-
lowering effects, have anti-inflam-
matory and immunomodulatory
properties [1]. These properties of
statins have suggested that they
could have beneficial effects in
immune mediated neurological
disorders [2, 3]. In particular,
lovastatin has been shown to in-
hibit the induction of inducible
nitric oxide synthase and proin-
flammatory cytokines in rat astro-
cytes, microglia and macrophages
[2] and to repress MHC-II medi-
ated T-cell activation [3]. Moreover,
lovastatin treatment decreased
neuroinflammatory activity and
clinical signs in experimental aller-
gic encephalomyelitis, an animal
model for multiple sclerosis (MS)
[4]. On the basis of these findings
we have begun to investigate
whether lovastatin could be a treat-
ment option for MS patients.
We report the results observed
on seven patients with the relaps-
ing-remitting MS after 12 months
of therapy with lovastatin. The
study was designed as a one-center,
open-label non placebo-controlled
trial. All the subjects were recruited
and treated on an outpatient basis,
at the MS clinic of the Neurology
Service of a general hospital. None
of the patients was on any im-
munossuppressive or immuno-
modulating therapy and none re-
ceived these agents during
lovastatin treatment. The study was
approved by the ethical committee
of our Hospital and a written in-
formed consent was provided from
all patients. Our cohort consisted
in women (age between 24 and 45
years) with a mean disease dura-
tion of 4.61 ± 2.16 years and clinical
evidence of disease activity as mea-
sured by at least two relapses
within the previous 2 years. Each
subject was treated with 20 mg of
lovastatin per day for one month
and the dose was increased to
40 mg per day if no adverse effects
were noted. A clinical examination
and hematology and biochemical
tests (including the plasma lipid
profile and creatine kinase) were
performed at baseline and every 3
months. Brain MRI was performed
at baseline and every 6 months.
During the follow-up, all clinical
evaluations were done without
knowledge of the neuroradiological
results.
No adverse events associated
with therapy were observed. Our
results (Table) show that the
Kurtzke Expanded Disability Status
Scale (EDSS) score was unchanged
in 6 patients and improved one
point in another patient after treat-
ment. Three patients were free of
relapses during therapy and for the
whole group the mean annual re-
lapse rate decreased during this pe-
riod. In four patients there was a
reduction of the inflammatory ac-
tivity of the disease after treatment
in comparison to baseline, as as-
sessed by the number of gadolin-
ium (Gd)-enhanced T1 lesions on
MRI. One patient did not have ac-
tive lesions at baseline and two en-
hanced lesions were seen at the end
of the study. In five patients, the
number of lesions on T2-weighted
images increased after treatment.
Lower post-treatment total choles-
terol levels provide evidence of
compliance with therapy.
The results from this short pilot






Table 1 Effects of lovastatin therapy on plasma cholesterol and disease activity in patients with multiple sclerosis
Before treatment At 12 months after treatment
Patient no EDSS* Annual Gd-enhanced T2-weighted Plasma total EDSS no of Gd-enhanced New T2- Plasma total
(age, years) Relapse lesions (no) lesions (no) cholesterolb relapses lesions (no) weighted cholesterol
Ratea mg/dl lesions (no) mg/dl
1 (45) 4.0 1.0 1 8 224 4.0 1 0 0 180
2 (34) 2.0 1.0 0 9 183 1.0 1 2 1 143
3 (44) 2.0 1.0 0 6 269 2.0 0 0 0 185
4 (27) 2.0 1.5 2 > 10 174 2.0 0 1 2 125
5 (28) 1.0 2.0 1 > 10 218 1.0 2 0 3 188
6 (24) 2.0 1.0 0 > 10 209 2.0 2 0 3 145
7 (35) 2.0 1.0 3 > 10 259 2.0 0 1 3 207
* Kurtzke Expanded Disability Status Scale
a Calculated on the basis of the number of relapses during the last 2 years; b The value in 30 normal subjects was 191.73±39.06 mg/dl
755
trial suggest that lovastatin treat-
ment may have favorable clinical
effects in patients with relapsing-
remitting MS. They support recent
data on peripheral blood mononu-
clear cells from MS patients indi-
cating that statins have immuno-
modulatory effects in part similar
to interferon beta [5]. Now there is
experimental evidence suggesting
that other statins, particularly sim-
vastatin [5] and atorvastatin [6]
could be beneficial in MS. More-
over, our data are in agreement
with the results of Pozzilli et al. [7]
showing a correlation between the
mean number of Gd-enhanced
MRI lesions and the mean plasma
level of total cholesterol. However,
the possible beneficial effects of
lowering plasma cholesterol sug-
gested by these data are presently
uncertain and deserve further
studies. We have observed that the
clinical response of MS patients to
interferon beta therapy is not asso-
ciated with alterations in plasma
total cholesterol and LDL-choles-
terol levels [8]. It should be noted
that statins might also suppress
inflammatory responses by choles-
terol-independent effects and inde-
pendent of 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase
inhibition [1]. As recently dis-
cussed, statins may interact with
multiple mechanisms involved in
the pathogenesis of MS [9, 10].
Nevertheless, our results also sug-
gest that caution is advisable. In
fact, MRI data provide evidence
that the majority of patients devel-
oped new brain lesions over the
time course of this study. In this
regard it is important to note that
statins also exhibit some potent
proinflammatory effects [5]. In ad-
dition, inhibition of cholesterol and
nonsterol isoprenoid synthesis by
these drugs could possibly interfere
with remyelination and neural re-
pair mechanisms in the MS lesion.
A recent study revealed that statins
in therapeutically relevant dosages
indeed affect human cerebral cho-
lesterol metabolism [11]. On the
basis of these findings we conclude
that further evaluation of statins as
therapeutic agents for MS should
be addressed in larger controlled
clinical trials and longer periods of
observation.
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